<< Back
First Post-Trial AbioCor Patient Passes Away

DANVERS, Mass.--(BUSINESS WIRE)--Sep. 1, 2009-- Abiomed, Inc. (NASDAQ: ABMD), has been informed by Mark Anderson, M.D., associate professor of surgery at UMDNJ-Robert Wood Johnson Medical School and chief of the section of cardiac surgery at both the medical school and Robert Wood Johnson University Hospital, that the first patient to receive the commercial AbioCorĀ® Total Replacement Heart, died on August 23, 2009, due to post-operative conditions unrelated to the device. The device was implanted in the patient in June 15, 2009 and was operating successfully, however the patient’s pre-existing medical conditions precluded a full recovery with the AbioCor.

The 76-year-old male patient was diagnosed with congestive, end-stage heart failure and did not qualify for a heart transplant or other available therapies, making him eligible for the AbioCor implant. This was the first patient to receive an AbioCor implant since the completion of clinical trials and Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration (FDA) on September 5, 2006. He is survived by his wife and other family members.

No further information is available at this time.

"Our thoughts and prayers are with the family," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release may contain forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Source: Abiomed, Inc.

Abiomed, Inc.
Aimee Maillett, 978-646-1553
Public Relations Specialist
ir@abiomed.com

Could not find file '\\aws.nasdaqomx.com\irwebpro\content3\IRXMLDATA\95\95629\Disclaimers.xml'.